Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: Data from the BP-CARE study

Journal of Hypertension

Volumn 31, Issue 10, 2013, Pages 2018-2024

  Brambilla, Gianmaria ^a   Bombelli, Michele ^a   Seravalle, Gino ^b   Cifkova, Renata ^c   Laurent, Stephane ^d   Narkiewicz, Krzysztof ^e   Facchetti, Rita ^a   Redon, Josep ^f   Mancia, Giuseppe ^b   Grassi, Guido ^a,g  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f UNIVERSITY OF VALENCIA   (Spain)

^g IRCCS MULTIMEDICA   (Italy)

Author keywords

Ambulatory blood pressure; Antihypertensive treatment; Cardiovascular risk; Resistant hypertension; Target organ damage

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EUROPE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SEX DIFFERENCE; TARGET ORGAN; WHITE COAT HYPERTENSION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE; EUROPE, EASTERN; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RENAL INSUFFICIENCY; RISK FACTORS; TREATMENT OUTCOME; WHITE COAT HYPERTENSION;

EID: 84884417789     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328363823f     Document Type: Article

References (26)

1. Illig KA, Levy M, Sanchez L, Trachiotis GD, Shanley C, Irwin E, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-tern outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006; 44:1213-1218.
2. Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR, ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008; 118:42-48.
3. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281.
4. Vaclav?k J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57:1069-1075.
5. Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Resistant hypertension. BMJ 2012; 345:e7473.
6. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet 2012; 380:591-600.
7. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076-1080.
8. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124:1046-1058.
9. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635-1642.
10. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.
11. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension-its identification and epidemiology. Nat Rev Nephrol 2012; 9:51-58.
12. Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol 2012; 27:386-391.
13. Barochiner J, Alfie J, Aparicio LS, Cuffaro PE, Rada MA, Morales MS, et al. Prevalence and clinical profile of resistant hypertension among treated hypertensive subjects. Clin Exp Hypertens 2012; [Epub ahead of print].
14. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
15. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. ESH position paper: renal denervation: an interventional therapy of resistant hypertension. J Hypertens 2012; 30:837-841.
16. Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med 2013; 64:233-247.
17. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58:811-817.
18. Grassi G, Cifkova R, Laurent S, Narkiewicz K, Redon J, Farsang C, et al. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BPCARE study. Eur Heart J 2011; 32:218-225.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
20. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44:84-93.
21. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137-147.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in, Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel, III). JAMA 2001; 285:2486-2497.
23. Seravalle GL, Volpe M, Ganz F, Magni L, Brambilla G, Dell'Oro R, et al. Neuroadrenergic profile in patients with resistant hypertension. J Hypertens 2011; 29:e141.
24. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Crowley K, et al., on Behalf of the REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2012; [Epub ahead of print].
25. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlof B, Poulter NR, ASCOT investigators. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011; 29:2004-2013.
26. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2010; 3:CD005182.